OKYO Pharma Limited (OKYO) 20-F 13 Aug 24 2024 FY Annual report (foreign) Financial data

Cover

Cover - shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Aug. 08, 2024
Entity Addresses [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	001-41386
Entity Registrant Name	OKYO Pharma Limited
Entity Central Index Key	0001849296
Entity Incorporation, State or Country Code	Y7
Entity Address, Address Line One	Martello Court
Entity Address, Address Line Two	Admiral Park
Entity Address, City or Town	St. Peter Port
Entity Address, Country	GG
Entity Address, Postal Zip Code	GY1 3HB
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Common Stock, Shares Outstanding			33,836,316
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	2814	1401
Auditor Name	PKF Littlejohn LLP	Forvis Mazars LLP
Auditor Location	London, England	London, England
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	107 Cheapside
Entity Address, City or Town	London
Entity Address, Country	GB
Entity Address, Postal Zip Code	EC2V 6DN
City Area Code	+44
Local Phone Number	20 7495 2379
Contact Personnel Name	Chief Financial Officer

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 826,848	$ 4,045,381
Current taxation receivable	559,128	559,128
Other receivables	151,938	592,195
Total current assets	1,537,914	5,196,704
Property and Equipment, net	3,350	7,216
Total non-current assets	3,350	7,216
Total assets	1,541,264	5,203,920
Current liabilities:
Trade and other payables	7,062,137	4,262,855
Related party payable	358,709	779,191
Loan payable to related party		2,215,111
Total current liabilities	7,420,846	7,257,157
Total liabilities	7,420,846	7,257,157
Shareholders’ Equity:
Share premium	143,112,687	131,385,892
Share options reserve	4,748,610	3,628,756
Warrants reserve	93,748	82,376
Foreign currency translation reserve	(11,311,447)	(11,452,542)
Retained deficit	(142,523,180)	(125,697,719)
Total shareholders’ equity	(5,879,582)	(2,053,237)
Total liabilities and shareholders’ equity	$ 1,541,264	$ 5,203,920

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	[1]
Operating expenses:
Research and development	$ (8,243,571)	$ (6,337,698)	$ (1,609,558)
Operating Expenses	(7,506,161)	(6,849,502)	(4,608,008)
Total operating expenses	(15,749,732)	(13,187,200)	(6,217,566)
Other (expense):
Finance expense	(1,053,313)	(96,687)
Loss from operations before income taxes	(16,803,045)	(13,283,887)	(6,217,566)
Income tax	(22,416)	12,202	786,521
Loss for the year	(16,825,461)	(13,271,685)	(5,431,045)
Other Comprehensive loss:
Exchange differences on translating foreign operations	141,095	(441,015)	(837,152)
Comprehensive loss	$ (16,684,366)	$ (13,712,700)	$ (6,268,197)
Basic loss per share attributable to common shareholders	$ (0.57)	$ (0.61)	$ (0.36)
Diluted loss per share attributable to common shareholders	$ (0.57)	$ (0.61)	$ (0.36)
[1]Refer to Note 2A and 18A

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($)	Issued capital [member]	Other reserves [member]	Warrant Reserves [member]	Convertible loan note reserve [member]	Retained earnings [member]	Translation reserve [member]	Total
Balance at Mar. 31, 2021	$ 111,629,173	$ 636,313	$ 861,214	$ 8,370,836	$ (106,003,753)	$ (10,174,375)	$ 5,319,408
Balance, shares at Mar. 31, 2021	10,351,020
Convertible loan note and warrant interest			546,318	444,918	(991,236)
Convertible loan note conversion	$ 8,876,397			(8,876,397)
Convertible loan note conversion, shares	4,847,483
Currency translation on Convertible Loan note conversion				654,833			654,833
Transfer between equity reserves			594,190	(594,190)
Options charge		1,737,876					1,737,876
Options forfeiture		(19,149)					(19,149)
Warrants Exercised	$ 3,470,940		(2,010,030)				1,460,910
Warrants Exercised, shares	5,946,271
Warrants charge			61,721				61,721
Total transactions	$ 12,347,337	1,718,727	(807,801)	(8,370,836)	(991,236)		3,896,191
Total transactions, shares	10,793,754
Loss for the period					(5,431,045)		(5,431,045)	[1]
Currency translation						(837,152)	(837,152)
Total comprehensive income					(5,431,045)	(837,152)	(6,268,197)	[1]
Balance at Mar. 31, 2022	$ 123,976,510	2,355,040	53,413		(112,426,034)	(11,011,527)	2,947,402
Balance, shares at Mar. 31, 2022	21,144,774
Issuance of shares fundraising net	$ 7,323,354						7,323,354
Issuance of shares fundraising net, shares	4,341,500
Expenses settled in shares	$ 86,028						86,028
Expenses settled in shares, shares	33,500
Options charge		1,286,128					1,286,128
Options forfeiture		(12,412)					(12,412)
Warrants charge			28,963				28,963
Total transactions	$ 7,409,382	1,273,716	28,963				8,712,061
Total transactions, shares	4,375,000
Loss for the period					(13,271,685)		(13,271,685)
Currency translation						(441,015)	(441,015)
Total comprehensive income					(13,271,685)	(441,015)	(13,712,700)
Balance at Mar. 31, 2023	$ 131,385,892	3,628,756	82,376		(125,697,719)	(11,452,542)	(2,053,237)
Balance, shares at Mar. 31, 2023	25,519,774
Issuance of shares fundraising net	$ 6,208,508						6,208,508
Issuance of shares fundraising net, shares	4,159,270
Expenses settled in shares	$ 2,368,287						2,368,287
Expenses settled in shares, shares	1,557,272
Issuance of shares, related party loan conversion	$ 3,150,000						3,150,000
Issuance of shares related party loan conversions, shares	2,100,000
Options charge		1,121,273					1,121,273
Options forfeiture		(1,419)					(1,419)
Warrants charge			11,372				11,372
Total transactions	$ 11,726,795	1,119,854	11,372				12,858,021
Total transactions, shares	7,816,542
Loss for the period					(16,825,461)		(16,825,461)
Currency translation						141,095	141,095
Total comprehensive income					(16,825,461)	141,095	(16,684,366)
Balance at Mar. 31, 2024	$ 143,112,687	$ 4,748,610	$ 93,748		$ (142,523,180)	$ (11,311,447)	$ (5,879,582)
Balance, shares at Mar. 31, 2024	33,336,316
[1]Refer to Note 2A and 18A

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss from operations before income taxes	$ (16,803,045)	$ (13,283,887)	$ (6,217,566)	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Share option charge	1,121,273	1,286,128	1,737,876
Warrant charge	11,372	28,963	61,721
Forfeiture of options	(1,419)	(12,412)	(19,149)
Depreciation of fixed assets	3,866	3,797	2,331
(Gain)/Loss on foreign exchange	55,183	51,192	(9,230)
Expenses settled in shares	3,452,769	86,028
Gain on disposal of right of use asset			(179)
Net decrease in related party receivables			27,376
Net increase/(decrease) in related party payables	(570,075)	814,319	48,900
Net (increase)/decrease in operating assets/other receivables	440,257	167,718	(802,154)
Net (decrease)/increase in trade and other payables	2,799,282	2,963,759	(297,991)
Cash inflow from taxation		199,153
Net cash used in operating activities	(9,490,537)	(7,695,242)	(5,468,065)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property, plant and equipment		(5,916)	(1,669)
Net cash used in investing activities		(5,916)	(1,669)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of ordinary shares		7,323,354
Proceeds from Fundraising, net	6,208,508
Processed from warrants exercised			2,153,270
Loan from related party		2,000,000
Net cash provided by financing activities	6,208,508	9,323,354	2,153,270
Net (decrease)/increase in cash and cash equivalents	(3,282,029)	1,622,196	(3,316,464)
Cash and cash equivalent, beginning of period	4,045,381	2,700,724	6,889,329
Exchange difference	63,496	(277,539)	(872,141)
Cash and cash equivalent, end of period	826,848	4,045,381	2,700,724
Non Cash items:
Conversion of related party loan into shares	$ 3,150,000
[1]Refer to Note 2A and 18A

Reporting Entity

Reporting Entity	12 Months Ended
	Mar. 31, 2024
Reporting Entity
Reporting Entity	Reporting Entity OKYO Pharma Limited (the “Company” or “OKYO”) is a company domiciled in Guernsey and listed on the main market on the NASDAQ Capital Market (NASDAQ: OKYO). The Company was previously dual listed with a standard listing on the main market of the London Stock Exchange (LSE: OKYO) until May 22, 2023 when it delisted from the standard segment of the main market of the London Stock Exchange. The Company is developing next-generation therapeutics to improve the lives of patients with dry eye diseases and chronic pain. Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through our collaboration with pioneer scientists in the field. The ultimate parent of the group is Panetta Partners Limited, incorporated in the British Virgin Islands.

ACCOUNTING POLICIES

ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2024
Disclosure of changes in accounting estimates [abstract]
ACCOUNTING POLICIES	2. ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently to all the years presented unless otherwise stated. Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008 as applicable to companies reporting under IFRS. Basis of measurement Going Concern The Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of March 31, 2024, had an accumulated deficit of $ 142.5 109 16.8 9.5 The Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that, without raising additional funding, the company will not be able to meet its liabilities as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at the end of July 2024 is approximately $ 0.3 0.4 2.6 The Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are more specialist investors focused on early-stage opportunities. The Company raised $ 2.5 11.4 The Directors are taking steps to put engagements and plans into place to ensure that sufficient funds will be forthcoming to progress the clinical pipeline. These steps include deferred payments of existing liabilities, working capital cost reductions and raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a material uncertainty that may cast significant doubt on the Group and Company’s ability to continue as a going concern, and therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be forthcoming and accordingly they have prepared these financial statements on a going concern basis. New and Revised Standards Standards in effect in 2024 There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1, 2023, that are relevant to the Group or that have had any material impact in the year to March 31, 2024. New standards, amendments to standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to have a material impact on the Group, and hence are not listed here. Basis of consolidation Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor’s return. The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated from the date at which control ceases. Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products. Taxation The tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance sheet date. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilised. In the current year, Research and Development tax credits are not provided for and are recognized when received. This policy is as a result of the UK tax authority’s new regime of reviewing nearly every tax claim it receives. In the year ended March 31, 2022, Research and Development tax credits were provided for in the year that the costs were incurred. These were estimated based on eligible research and development expenditure. Any difference compared to the amount rebated is recognized when the cash is received from the UK tax authorities. Foreign currency translation Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency), which is Pounds sterling. The consolidated financial statements are presented in US dollars, which is the Group’s presentation currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. The financial statements are translated into US dollars on the following basis: ● Assets and liabilities at the rate of exchange ruling at the year-end date. ● Profit and loss account items at the average rate of exchange for the year. Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation. License fees Payments related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic benefits from the asset will flow to the Group and the cost of the asset can be reliably measured. Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Licence fees expenses are recognised as incurred. Research and development All on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group’s products, the criteria for development costs to be recognised as an asset, as set out in IAS 38 ‘Intangible Assets’, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no such qualifying expenditure. Financial instruments The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement At initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement At initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Group’s financial liabilities include trade and other payables. Cash and cash equivalents Cash and cash equivalents comprise cash at bank and on hand. Impairment Impairment of financial assets measured at amortised cost At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost. In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets. General approach The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents. Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses. Simplified approach The simplified approach is applied to the impairment assessment of other receivables. Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses. Impairment of non-financial assets i) Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. ii) Non-financial assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value. Share capital Ordinary shares of the Company are classified as equity. Property, plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the revaluation reserve are transferred to retained earnings. (ii) Depreciation Depreciation is calculated on the depreciable amount, which is the cost of an asset, less its residual value. Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and equipment. The estimated useful lives for the current period and the comparative period are as follows: DISCLOSURE OF ESTIMATED USEFUL LIVES IT and equipment 3 Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the statement of comprehensive income. Leases All leases are accounted for by recognising a right-of-use asset and a lease liability except for: ● Leases of low value assets; and ● Leases with a duration of 12 months or less. The Group has leases for its offices. The group does not have leases greater than 12 months. There are no leases reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. At lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group’s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee entity have a different risk profile to that of the Group. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. Short term leases exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit and loss on a straight-line basis over the term of the lease. Share based payments The calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the Company’s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of the awards. Where employees, Directors or advisers are rewarded using share based payments, the fair value of the employees’, Directors’ or advisers’ services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). In accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share based payment reserve – options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding credit is made to a share based payment reserve – warrants, in the case of warrants issued in return for services. Warrants Warrants are issued by the Group in return for services and as part of a financing transaction. Warrants issued in return for services. Warrants issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value. Warrants issued as part of a financing transaction. Warrants issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured. Classification of these instruments is governed by the so-called ‘fixed’ test for non-derivatives, and the ‘fixed for fixed’ test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments. Warrants issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification. Fair Value Measurement Management have assessed the categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows; Level 1 - valued using quoted prices in active markets for identical assets; Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1; Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data. 2A. RECLASSIFICATION OF PRIOR YEAR PRESENTATION Certain amounts for the year ended March 31, 2022 have been reclassified for consistency with the current year and year ended March 31, 2023 presentation. These reclassifications had no effect on the reported results of operations. For a more accurate representation of research and development expenses, an adjustment has been made to the Consolidated statement of Operations and comprehensive loss for the year ended March 31, 2022, to reclassify patent related expenditure to research and development expenses from operating expenses. The impact of the reclassification on the Group’s Consolidated statement of operations and comprehensive loss is as follows: SCHEDULE OF RECLASSIFICATION OF CONSOLIDATED STATEMENT OF OPERATIONS Consolidated statement of operations and comprehensive loss Year ended March 31, 2022 As Previously reported Adjustment As restated $ $ $ Research and development (1,301,178 ) (308,380 ) (1,609,558 ) Operating expenses (4,916,388 ) 308,380 (4,608,008 ) Total operating expenses (6,217,566 ) - (6,217,566 ) Total Comprehensive loss for the year (6,268,197 ) - (6,268,197 )

CRITICAL ACCOUNTING JUDGEMENTS

CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY	12 Months Ended
	Mar. 31, 2024
Critical Accounting Judgements And Key Sources Of Estimation Uncertainty
CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY	3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY The preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being IFRS as issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based on historical experience and other factors, including expectations of future events. The following are considered to be the key sources of estimation uncertainty : Share-based payments The Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on the grant date. The Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that have to be met as conditions to vesting. The Group makes estimates as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest rate for the term of the award and correlations and volatilities of the shares of peer group companies. The Group also makes estimates as to the vesting period for awards that have performance-based criteria. The resulting cost of an equity incentive award is recognised as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognised over the vesting period using the straight-line method. The assumptions used for estimating fair value for share-based payment transactions are disclosed in note 14 to our consolidated financial statements.

OPERATING EXPENSES

OPERATING EXPENSES	12 Months Ended
	Mar. 31, 2024
Expenses by nature [abstract]
OPERATING EXPENSES	4. OPERATING EXPENSES Operating expenses are stated after charging/(crediting): SCHEDULE OF OPERATING EXPENSES Group 2024 $ 2023 $ 2022 $ Year Ended March 31, Group 2024 $ 2023 $ 2022 $ Director fees including bonus (excluding Chairman’s bonus) 1,100,192 910,403 707,385 Chairman’s bonus 934,007 300,000 - Auditor’s Remuneration (refer to Note 20) * 158,195 454,692 349,665 Legal and Professional fees 1,377,774 1,432,926 1,143,300 (Gain)/Loss on disposal of leases - - (179 ) FX Gains and losses 55,183 99,930 (13,577 ) Depreciation 3,866 3,797 2,423 * This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

SEGMENTAL REPORTING

SEGMENTAL REPORTING	12 Months Ended
	Mar. 31, 2024
Disclosure of operating segments [abstract]
SEGMENTAL REPORTING	5. SEGMENTAL REPORTING During the year under review management identified the Group’s only operating segment as the research and development of biotechnological and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual financial statements.

EMPLOYEES INCLUDING OFFICERS, E

EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS	12 Months Ended
	Mar. 31, 2024
Employees Including Officers Executive And Non-executive Directors
EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS	6. EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY 2024 $ 2023 $ 2022 $ Year ended March 31, 2024 $ 2023 $ 2022 $ Group Staff costs comprised: Directors’ salaries 2,039,447 1,204,285 707,385 Wages and salaries 612,076 548,328 323,186 Social security costs 11,386 151,967 84,449 Recruitment costs - 13,750 14,259 Total employee benefits expense 2,662,909 1,918,330 1,129,279 The average monthly number of employees, including directors, employed by the group during the years ending March 31, 2024, March 31, 2023, and March 31, 2022 were: Research and Development 2 2 2 Corporate and administration 5 6 5 7 8 7 The Group and Company made $ 5,598 6,510 2,622

REMUNERATION OF KEY MANAGEMENT

REMUNERATION OF KEY MANAGEMENT PERSONNEL	12 Months Ended
	Mar. 31, 2024
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
REMUNERATION OF KEY MANAGEMENT PERSONNEL	7. REMUNERATION OF KEY MANAGEMENT PERSONNEL Directors of the Group and Company received the following remuneration during the years ended March 31, 2024 and 2023: SCHEDULE OF REMUNERATION OF DIRECTORS Year ended March 31, 2024 2023 $’000 Directors’ Bonus Salary Share based payment expenses Directors’ Bonus Salary Share based payment expenses G. Cerrone (1) 376 934 - - 145 300 - - G Jacob - 196 392 526 - 217 433 834 W Simon 40 - - 10 39 - - - J Brancaccio 56 - - 30 39 - - 24 B Denoyer (3) 40 - - 11 39 - - 18 512 1,130 392 577 262 517 433 876 Year ended March 31, $’000 2022 Directors Bonus Salary Share based G. Cerrone (1) 164 - - - G Jacob - 75 350 1,579 W Simon 44 - - 1 K. Shailubhai (2) 18 - - (15 ) J Brancaccio 42 - - 20 B Denoyer (3) 15 - - 4 283 75 350 1,589 (1) Gabriele Cerrone’s bonus awarded for $ 939 614 320 Gabriele Cerrone’s bonus awarded for $ 300 150 150 (2) K Shailubhai resigned as Director on 17 June 2021 (3) Bernard Denoyer was appointed as Director on 24 November 2021 The following share options were granted to Directors in the year: SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS 2024 2023 2022 Number of Number of Number of J Brancaccio 60,000 15,385 15,385 G Jacob 50,000 84,615 200,000 W Simon 60,000 6,154 - B Denoyer 10,000 3,077 15,384 180,000 109,231 230,769 No director has yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share options in the year. The Key Management Personnel of the Group are members of the leadership team who have the authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly. They include all Directors of the Board (executive and non-executive). Key Management Personnel compensation is set out below. SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION 2024 2023 2022 $’000 $’000 $’000 Short-term employee benefits 2,559 1,500 1,026 Share based payments 1,005 1,273 1,815 Total 3,564 2,773 2,841

TAXATION

TAXATION	12 Months Ended
	Mar. 31, 2024
Deferred tax expense (income) [abstract]
TAXATION	8. TAXATION SCHEDULE OF TAX CREDIT PERIOD Year ended March 31, 2024 $ 2023 $ 2022 $ Group Current year tax charge/(credit) 55,280 - (509,282 ) Adjustments in respect of prior periods (32,864 ) (12,202 ) (277,239 ) Deferred tax Origination and reversal of timing differences - - - Total tax charge/(credit) for the period 22,416 (12,202 ) (786,521 ) The tax charge/(credit) for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows: Loss before taxation (16,803,045 ) (13,283,888 ) (6,217,566 ) Loss charged at standard rate of corporation tax 19 (3,192,578 ) (2,523,939 ) (1,181,337 ) Tax losses arising in the year not recognized 3,032,344 2,279,050 524,870 Tax losses surrendered for Research and Development - - 667,335 Expenses not deductible for taxation 220,187 241,985 370,306 Tax increase from effect of capital allowances and depreciation 748 124 (3 ) Research and Development tax claim - - (509,282 ) Research and Development enhanced expenditure - - (377,187 ) Research and Development tax credits claimed in respect of previous periods (32,864 ) (12,202 ) (277,240 ) Consolidation adjustment in relation to foreign exchange movements (5,421 ) 2,780 (3,983 ) Total tax charge/(credit) for the period 22,416 (12,202 ) (786,521 ) No deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable. The Group has tax losses of $ 38,992,275 23,903,092 15,870,525 .

FINANCE INCOME AND COSTS

FINANCE INCOME AND COSTS	12 Months Ended
	Mar. 31, 2024
FINANCE INCOME AND COSTS	9. FINANCE INCOME AND COSTS SCHEDULE OF FINANCE COST 2024 $ 2023 $ 2022 $ Year ended March 31, 2024 $ 2023 $ 2022 $ Finance Income Interest income - - - Total finance income - - - Finance Expenses Interest expense on lease liabilities - - - Interest expense on related party loan (1,053,313 ) (96,687 ) - Total finance expenses (1,053,313 ) (96,687 ) -

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Mar. 31, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY, PLANT AND EQUIPMENT	10. PROPERTY, PLANT AND EQUIPMENT Details of the Group’s property, plant and equipment are as follows: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT $ IT equipment Total Cost At 1 April 2023 15,315 15,315 Additions - - Disposals (5,037 ) (5,037 ) Foreign exchange 189 189 At March 31, 2024 10,467 10,467 Depreciation At 1 April 2023 8,099 8,099 Charge in year 3,866 3,866 Write Off Disposals (5,037 ) (5,037 ) Foreign exchange 189 189 At March 31, 2024 7,117 7,117 Net Book Value as at March 31, 2024 3,350 3,350 $ IT equipment Total Cost At April 1, 2022 9,779 9,779 Additions 5,916 5,916 Disposals - - Foreign exchange (380 ) (380 ) At March 31, 2023 15,315 15,315 Depreciation At April 1, 2022 4,554 4,554 Charge in year 3,797 3,797 Foreign exchange (252 ) (252 ) At March 31, 2023 8,099 8,099 Net Book Value as at March 31, 2023 7,216 7,216 The Group’s property, plant and equipment is located in the following operating segments: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT Group Net Book Value $ UK 1,859 US 1,491 Total 3,350 Property, plant and equipment 3,350 Group Net Book Value $ UK 3,433 US 3,783 Total 7,216 Property, plant and equipment 7,216

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Receivables
PREPAID EXPENSES AND OTHER RECEIVABLES	11. PREPAID EXPENSES AND OTHER RECEIVABLES SUMMARY OF PREPAID EXPENSES AND OTHER RECEIVABLES $ 2024 2023 Year ended March 31, $ 2024 2023 Group Other receivables 5,585 340,848 VAT receivable 16,227 80,099 Prepayments 130,126 171,248 Prepaid expenses and other receivables 151,938 592,195 There are no differences between the carrying amount and fair value of any of the trade and other receivables above. Prepayments includes no prepaid invoices relating to the OK-101 project.

TRADE AND OTHER PAYABLES

TRADE AND OTHER PAYABLES	12 Months Ended
	Mar. 31, 2024
Trade and other payables [abstract]
TRADE AND OTHER PAYABLES	12. TRADE AND OTHER PAYABLES SCHEDULE OF TRADE AND OTHER PAYABLES $ 2024 2023 Year ended March 31, $ 2024 2023 Group Trade payables 6,128,132 2,314,581 Other payables 103,830 73,197 Accruals 504,657 1,545,410 Bonus accrual 325,518 329,667 Trade and other payables 7,062,137 4,262,855

CAPITAL AND RESERVES

CAPITAL AND RESERVES	12 Months Ended
	Mar. 31, 2024
Issued capital [abstract]
CAPITAL AND RESERVES	13. CAPITAL AND RESERVES Capital Management For the purpose of the Company’s capital management, capital includes called up share capital, share premium, share based payments for options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected in the statement of financial position. The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to maximise shareholder value through the optimisation of the debt and equity balance. The Company manages its capital to maximise the return to the shareholders through the optimisation of equity. The capital structure of the Company as at March 31, 2024 and 2023 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and retained deficit as disclosed. The Company manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares and release the Company’s share premium account. No changes were made in the objectives, policies or processes during the year ended March 31, 2024 and March 31, 2023. Share capital and premium The Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time. Each share in the Company confers upon the shareholder: ● the right to one vote at a meeting of the shareholders or on any resolution of shareholders; ● the right to an equal share in any dividend paid by the Company; and ● the right to an equal share in the distribution of the surplus assets of the Company on its liquidation. The Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations set out in the Company’s Articles of Incorporation. On May 22, 2023, the Company delisted from the standard segment of the Main Market of the London Stock Exchange and had a sole listing on the NASDAQ capital market. In conjunction with the delisting, there was a share consolidation of 65 to 1. The effect of the share consolidation has been reflected below for all periods. The Company is authorized to issue an unlimited number of nil par value shares of a single class. SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES Shares Share capital Issued ordinary shares of US$0.00 each Number $ At March 31, 2022 per 20-F Annual Report 1,374,415,468 123,976,510 Group Reorganization : Share Consolidation 65 to 1 Restated at 31 March 2022 21,144,745 123,976,510 Issue of share (IPO) – May 2022 625,000 2,500,000 Issue of share (IPO) – Cost of fundraising – May 2022 - (742,979 ) Expenses settled in shares 33,500 86,028 Issue of share (IPO) – March 2023 3,716,529 5,741,335 Issue of share (IPO) – Cost of fundraising – March 2023 - (175,000 ) At March 31, 2023 25,519,774 131,385,892 Issue of share for fundraising, net Sept-Dec 2023 4,159,270 6,208,508 Expenses settled in shares 1,557,272 2,368,287 Issuance of Shares to related party – Loan Conversion 2,100,000 3,150,000 At March 31, 2024 33,336,316 143,112,687 Share options reserve The share-based payment reserve for options represents the cost to issue share-based compensation, primarily share options, based on their grant date fair value. Share warrants reserve The share-based payment reserve for warrants represent the cost to issue warrants based on their grant date fair value. Convertible Loan Note reserve The convertible loan note reserve represents the proceeds received on issuance of convertible loan notes classified as equity instruments, accrued interest and any relative fair value adjustments. Retained Deficit reserve Retained deficit represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders. Translation reserve The translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group. Dividends The Directors paid no

SHARE OPTIONS AND WARRANTS

SHARE OPTIONS AND WARRANTS	12 Months Ended
	Mar. 31, 2024
Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]
SHARE OPTIONS AND WARRANTS	14. SHARE OPTIONS AND WARRANTS Options The Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market price of an ordinary share in the Company at the date of grant. In May 2023, the company delisted from the Main Market of the London Stock Exchange and carried out a share consolidation of 65 to 1. The effect of the share consolidation has been reflected below for all periods in the calculation of the number of options issued and the weighted average exercise price. SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE 2024 2023 Options Weighted Options Weighted Outstanding at April 1 1,696,451 3.85 1,113,841 4.86 Granted 727,500 1.53 612,610 1.04 Forfeited (2,301 ) 2.13 (30,000 ) - Exercised - - - - Outstanding at March 31 2,421,650 3.34 1,696,451 3.85 Exercisable at March 31 894,956 4.34 560,082 4.41 2022 Options Weighted Outstanding at April 1 934,615 4.48 Granted 433,072 5.46 Forfeited (253,846 ) 3.84 Exercised - - Outstanding at March 31 1,113,841 4.86 Exercisable at March 31 222,115 4.78 During the years ending March 31, 2024, March 31, 2023, and March 31, 2022 no The total outstanding fair value charge of the share option instruments is deemed to be approximately $ 1,146,835 1,649,386 1,119,854 1,273,716 1,419 12,412 The weighted average contractual life of options outstanding at March 31, 2024 is 7.60 5.73 Share options outstanding at the end of the year have the following expiry dates and exercise prices: SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES Grant Date Expiry Date Exercise Price $ Share Options as at March 31, 2024 July 6, 2018 July 6, 2025 3.69 30,769 August 20, 2020 August 19, 2028 12.72 11,538 January 6, 2021 January 5, 2031 4.10 615,384 January 21, 2021 January 11, 2031 6.48 23,076 April 15, 2021 April 15, 2031 6.47 76,923 August 31, 2021 August 31, 2031 4.02 221,538 January 31,2022 January 30, 2032 6.57 134,613 August 1, 2022 July 31,2027 4.10 10,000 September 20, 2022 September 19, 2027 4.10 28,000 November 22,2022 November 23,2022 5.13 76,923 March 14, 2023 March 13, 2027 1.85 465,386 July 26, 2023 July 26,2033 1.53 260,000 October 20, 2023 October 20, 2033 1.57 85,000 November 20, 2023 November 20, 2033 1.71 65,000 November 24, 2023 November 24,2033 1.65 40,000 March 1, 2024 March 1,2034 1,33 20,000 March 13, 2024 March 13, 2034 1.46 257,500 Total 2,421,650 Fair value of options granted The Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions below. Historical volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable to the Company and in part on the company’s own share price volatility. Where sufficient historical data is available, the Company uses its own share price to calculate volatility. The Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital in the foreseeable future. The Company has estimated a forfeiture rate of zero. The model inputs for options granted during the year ended March 31, 2024 valued under the Black Scholes Valuation model are: SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED Grant Date March 1, 2024 March 13, 2024 Grant date share price $ 1.33 $ 1.46 Exercise share price $ 1.33 $ 1.46 Vesting periods 50% over two years 33.3% over three years Risk free rate 4.18 % 4.19 % Expected volatility 91.0 % 91.0 % Option life 4 4 Grant Date July 26, October 20, November 20, November 24, Grant date share price $ 1.53 $ 1.57 $ 1.71 $ 1.65 Exercise share price $ 1.53 $ 1.57 $ 1.71 $ 1.65 Vesting periods 25% over four years 33.3% over three years 25% over four years 25% over four years Risk free rate 3.91 % 4.31 % 3.70 % 3.91 % Expected volatility 68.8 % 72.0 % 72.0 % 72.0 % Option life 4 4 4 4 The model inputs for options granted during the year ended March 31, 2023 valued under the Black Scholes Valuation model are: Grant Date August 1, September 20, November 22, March 14, Grant date share price 5 p 5 p 6.3 p 2.5 p Exercise share price 5 p 5 p 6.3 p 2.5 p Vesting periods 25% each quarter 100% in one year Fully vested 25% over four years Risk free rate 1.47 % 3.26 % 3.16 % 3.2 % Expected volatility 81.2 % 81.8 % 68.3 % 125 % Option life 2 2 2 4 Warrants On May 22, 2023, the Company delisted from the standard segment of the Main Market of the London Stock Exchange and had a sole listing on the NASDAQ capital market. In conjunction with the delisting, there was a share consolidation of 65 to 1. The effect of the share consolidation has been reflected below for all periods. As part of the acquisition of the OK-101 project, the underlying scientific founders of the OK-101 Project (inukshuk Holdings), who will continue to be involved in the development of the Project, received 563,986 292.5 In May 2020, warrants were granted over 13,986 178.75 No SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE March 31, 2024 March 31, 2023 Warrants Weighted Average exercise price (cents) Warrants Weighted Average exercise price (cents) Outstanding at April 1 563,986 397 563,986 397 Granted - - - - Exercised - - - - Outstanding at March 31 563,986 397 563,986 397 Exercisable at March 31 307,692 221 13,986 221 The Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions below. The remaining fair value of the warrant instruments is nil 11,194 28,963 61,721

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Mar. 31, 2024
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	15. FINANCIAL INSTRUMENTS The main risks arising from the Group’s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors regularly review and agree policies for managing each of these risks which are summarized below. Liquidity risk The Group’s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated from by private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group’s financial liabilities based on contractual undiscounted payments: SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS $ Less than 3 3 to 12 months Total Group 2024 $ Less than 3 3 to 12 months Total Trade and other payables 1,028,764 6,033,373 7,062,137 Related party payables 25,019 333,690 358,709 Total 1,053,783 6,367,063 7,420,846 $ Less than 3 3 to 12 months Total Group 2023 $ Less than 3 3 to 12 months Total Trade and other payables 2,800,918 1,461,937 4,262,855 Related party payables - 2,994,302 2,994,302 Total 2,800,918 4,456,239 7,257,157 Credit risk Credit risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their internal reporting and assess outstanding receivables for ability to be repaid. Interest rate risk The Group has limited exposure to interest-rate risk arising from its bank deposits and convertible loan note instruments. These deposit accounts are held at variable interest rates based on Barclays Bank plc, Alpha Group International plc, Wells Fargo and Penn Community Bank base rates. The Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity position at the year-end for either the year ended March 31,2024 or March 31, 2023.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2024
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	16. RELATED PARTY TRANSACTIONS All related party transactions occurred in the normal course of operations. Tiziana Life Sciences Ltd Tiziana Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. The Company shares premises and other resources with Tiziana Life Sciences Ltd and there is a shared services agreement in place between the Company and Tiziana Life Sciences Ltd. As at March 31, 2024, the Company had incurred $ 139,963 159,501 297,870 184,150 Tiziana Life Sciences Ltd also paid other invoices on behalf of the Company. As of March 31, 2024, Tiziana had paid $ 35,347 433,140 230,000 75,267 In August 2022, Tiziana Life Sciences Ltd issued a short-term credit facility to OKYO Pharma for $ 2 The loan was available for a period of 6 months upon first draw-down and carries an interest rate of 16% 4% In February 2023, Tiziana Life Sciences Ltd issued an additional short-term credit facility to OKYO Pharma for $ 0.5 488,009 7,902 7,902 2,000 1,150 2,100,000 Directors – (See Note 7 also) At March 31, 2024, the Company owed John Brancaccio $ 13,408 At March 31, 2024, the Company owed Bernard Denoyer $ 13,408 At March 31, 2024, the Company owed Gary Jacobs $ 29,167 At March 31, 2024, the Company owed Willy Simon $ 13,408 At March 31, 2024 the Company owed Gabriele Cerrone $ 62,850

BASIC AND DILUTED LOSS PER SHAR

BASIC AND DILUTED LOSS PER SHARE	12 Months Ended
	Mar. 31, 2024
Earnings per share [abstract]
BASIC AND DILUTED LOSS PER SHARE	17. BASIC AND DILUTED LOSS PER SHARE Basic loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary shares in issue during the year. In May 2023, the company delisted from the Main Market of the London Stock Exchange and carried out a share consolidation of 65 to 1. The weighted average number of ordinary shares in issue shown below has been retrospectively adjusted to reflect this share consolidation. As such, the number of shares presented below may not be consistent with that presented elsewhere. SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS Year ended 2024 2023 (Loss) attributable to equity holders of the company ($) (16,825,461 ) (13,271,685 ) Weighted average number of ordinary shares in issue (adjusted) 29,343,727 22,257,058 Basic and dilutive loss per share (dollars per share) (0.57 ) (0.61 ) Year ended 2022 (Loss) attributable to equity holders of the company ($) (5,431,045 ) Weighted average number of ordinary shares in issue (adjusted) 15,064,813 Basic and dilutive loss per share (dollars per share) (0.36 ) As the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented on the face of the Statement of comprehensive income are therefore identical.

LEASES

LEASES	12 Months Ended
	Mar. 31, 2024
Presentation of leases for lessee [abstract]
LEASES	18. LEASES The Group is a lessee and does not have any leases as a lessor. All leases are accounted for by recognising a right-of-use asset and a lease liability except for: ● Leases of low value assets; and ● Leases with a duration of 12 months or less. The Group has leases for its offices. The Group does not have leases of low value assets. The group does not have leases greater than 12 months. For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. During the year to March 31, 2022, the Group entered into new lease agreement on its existing office. The new leases has a term shorter than 12 months, so the Group has applied the exemption allowed by paragraph 5a in IFRS 16 in respect of short term leases. Operating leases At March 31, 2024 and March 31, 2023, the company had annual commitments under non-cancellable operating leases: SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES Operating leases which expire: March 31, 2024 March 31, 2023 $ $ Within one year 6,660 6,000

AUDITOR_S RENUMERATION

AUDITOR’S RENUMERATION	12 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
AUDITOR’S RENUMERATION	19. AUDITOR’S RENUMERATION During the period, the group obtained the following services from the company’s auditors PKF, our independent registered public accounting firm and Mazars, our previous independent registered public accounting firm.: SCHEDULE OF COMPANY AUDITORS FEES Mazars LLP March 31, 2024 March 3,1 2023 March 31, 2022 $ $ $ Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements - 106,927 200,773 Fees payable to the company’s auditors for other services: Audit-related assurance services 7,354 227,208 148,892 Total auditor’s remuneration 7,354 334,135 349,665 PKF Littlejohn LLP March 31, 2024 March 31, 2023 March 31, 2022 $ $ $ Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements 125,701 120,557 - Fees payable to the company’s auditors for other services: Audit-related assurance services 25,140 - - Total auditor’s remuneration 150,841 120,557 -

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Mar. 31, 2024
Cash and cash equivalents [abstract]
CASH AND CASH EQUIVALENTS	20. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following: SCHEDULE OF CASH AND CASH EQUIVALENT March 31, 2024 March 31, 2023 $ $ Cash at bank and in hand: GBP 275,342 471,974 EURO 898 - USD 550,608 3,573,407 826,848 4,045,381

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2024
COMMITMENTS AND CONTINGENCIES	21. COMMITMENTS AND CONTINGENCIES The Group’s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical, clinical and commercial milestone obligations are not provided for until there is a reasonable certainty that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain. ● OK-101 – We are obligated to pay to On Target Therapeutics the following additional amounts in respect of the first licensed product or service which achieves the stated development milestones: SCHEDULE OF MILESTONES PAYMENT (a) First Patient Enrolled in a Phase I Human Clinical trial $ 300,000 (b) First Patient Enrolled in a Phase II Human Clinical trial $ 600,000 (c) First Patient Enrolled in a Phase III Human Clinical trial $ 1,500,000 ● BAM8 – The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance fee is $ 15,000 10,000

POST BALANCE SHEET EVENTS

POST BALANCE SHEET EVENTS	12 Months Ended
	Mar. 31, 2024
Disclosure of non-adjusting events after reporting period [abstract]
POST BALANCE SHEET EVENTS	22. POST BALANCE SHEET EVENTS There are no post balance sheet events to report.

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2024
Disclosure of changes in accounting estimates [abstract]
Basis of preparation	Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008 as applicable to companies reporting under IFRS.
Basis of measurement	Basis of measurement
Going Concern	Going Concern The Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of March 31, 2024, had an accumulated deficit of $ 142.5 109 16.8 9.5 The Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that, without raising additional funding, the company will not be able to meet its liabilities as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at the end of July 2024 is approximately $ 0.3 0.4 2.6 The Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are more specialist investors focused on early-stage opportunities. The Company raised $ 2.5 11.4 The Directors are taking steps to put engagements and plans into place to ensure that sufficient funds will be forthcoming to progress the clinical pipeline. These steps include deferred payments of existing liabilities, working capital cost reductions and raising additional equity. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a material uncertainty that may cast significant doubt on the Group and Company’s ability to continue as a going concern, and therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this material uncertainty, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be forthcoming and accordingly they have prepared these financial statements on a going concern basis. New and Revised Standards Standards in effect in 2024 There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1, 2023, that are relevant to the Group or that have had any material impact in the year to March 31, 2024. New standards, amendments to standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to have a material impact on the Group, and hence are not listed here.
Basis of consolidation	Basis of consolidation Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor’s return. The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated from the date at which control ceases. Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Segment reporting	Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products.
Taxation	Taxation The tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance sheet date. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilised. In the current year, Research and Development tax credits are not provided for and are recognized when received. This policy is as a result of the UK tax authority’s new regime of reviewing nearly every tax claim it receives. In the year ended March 31, 2022, Research and Development tax credits were provided for in the year that the costs were incurred. These were estimated based on eligible research and development expenditure. Any difference compared to the amount rebated is recognized when the cash is received from the UK tax authorities.
Foreign currency translation	Foreign currency translation Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency), which is Pounds sterling. The consolidated financial statements are presented in US dollars, which is the Group’s presentation currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. The financial statements are translated into US dollars on the following basis: ● Assets and liabilities at the rate of exchange ruling at the year-end date. ● Profit and loss account items at the average rate of exchange for the year. Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.
License fees	License fees Payments related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic benefits from the asset will flow to the Group and the cost of the asset can be reliably measured. Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Licence fees expenses are recognised as incurred.
Research and development	Research and development All on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group’s products, the criteria for development costs to be recognised as an asset, as set out in IAS 38 ‘Intangible Assets’, are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.
Financial instruments	Financial instruments The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement At initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement At initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Group’s financial liabilities include trade and other payables.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents comprise cash at bank and on hand.
Impairment	Impairment Impairment of financial assets measured at amortised cost At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost. In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets. General approach The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents. Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses. Simplified approach The simplified approach is applied to the impairment assessment of other receivables. Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses. Impairment of non-financial assets i) Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. ii) Non-financial assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value.
Share capital	Share capital Ordinary shares of the Company are classified as equity.
Property, plant and equipment	Property, plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the revaluation reserve are transferred to retained earnings. (ii) Depreciation Depreciation is calculated on the depreciable amount, which is the cost of an asset, less its residual value. Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and equipment. The estimated useful lives for the current period and the comparative period are as follows: DISCLOSURE OF ESTIMATED USEFUL LIVES IT and equipment 3 Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the statement of comprehensive income.
Leases	Leases All leases are accounted for by recognising a right-of-use asset and a lease liability except for: ● Leases of low value assets; and ● Leases with a duration of 12 months or less. The Group has leases for its offices. The group does not have leases greater than 12 months. There are no leases reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. At lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the Group’s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate is adjusted should the lessee entity have a different risk profile to that of the Group. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. Short term leases exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit and loss on a straight-line basis over the term of the lease.
Share based payments	Share based payments The calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the Company’s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of the awards. Where employees, Directors or advisers are rewarded using share based payments, the fair value of the employees’, Directors’ or advisers’ services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). In accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share based payment reserve – options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding credit is made to a share based payment reserve – warrants, in the case of warrants issued in return for services.
Warrants	Warrants Warrants are issued by the Group in return for services and as part of a financing transaction. Warrants issued in return for services. Warrants issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value. Warrants issued as part of a financing transaction. Warrants issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured. Classification of these instruments is governed by the so-called ‘fixed’ test for non-derivatives, and the ‘fixed for fixed’ test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments. Warrants issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.
Fair Value Measurement	Fair Value Measurement Management have assessed the categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows; Level 1 - valued using quoted prices in active markets for identical assets; Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1; Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.
RECLASSIFICATION OF PRIOR YEAR PRESENTATION	2A. RECLASSIFICATION OF PRIOR YEAR PRESENTATION Certain amounts for the year ended March 31, 2022 have been reclassified for consistency with the current year and year ended March 31, 2023 presentation. These reclassifications had no effect on the reported results of operations. For a more accurate representation of research and development expenses, an adjustment has been made to the Consolidated statement of Operations and comprehensive loss for the year ended March 31, 2022, to reclassify patent related expenditure to research and development expenses from operating expenses. The impact of the reclassification on the Group’s Consolidated statement of operations and comprehensive loss is as follows: SCHEDULE OF RECLASSIFICATION OF CONSOLIDATED STATEMENT OF OPERATIONS Consolidated statement of operations and comprehensive loss Year ended March 31, 2022 As Previously reported Adjustment As restated $ $ $ Research and development (1,301,178 ) (308,380 ) (1,609,558 ) Operating expenses (4,916,388 ) 308,380 (4,608,008 ) Total operating expenses (6,217,566 ) - (6,217,566 ) Total Comprehensive loss for the year (6,268,197 ) - (6,268,197 )

ACCOUNTING POLICIES (Tables)

ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2024
Disclosure of changes in accounting estimates [abstract]
DISCLOSURE OF ESTIMATED USEFUL LIVES	The estimated useful lives for the current period and the comparative period are as follows: DISCLOSURE OF ESTIMATED USEFUL LIVES IT and equipment 3
SCHEDULE OF RECLASSIFICATION OF CONSOLIDATED STATEMENT OF OPERATIONS	The impact of the reclassification on the Group’s Consolidated statement of operations and comprehensive loss is as follows: SCHEDULE OF RECLASSIFICATION OF CONSOLIDATED STATEMENT OF OPERATIONS Consolidated statement of operations and comprehensive loss Year ended March 31, 2022 As Previously reported Adjustment As restated $ $ $ Research and development (1,301,178 ) (308,380 ) (1,609,558 ) Operating expenses (4,916,388 ) 308,380 (4,608,008 ) Total operating expenses (6,217,566 ) - (6,217,566 ) Total Comprehensive loss for the year (6,268,197 ) - (6,268,197 )

OPERATING EXPENSES (Tables)

OPERATING EXPENSES (Tables)	12 Months Ended
	Mar. 31, 2024
Expenses by nature [abstract]
SCHEDULE OF OPERATING EXPENSES	Operating expenses are stated after charging/(crediting): SCHEDULE OF OPERATING EXPENSES Group 2024 $ 2023 $ 2022 $ Year Ended March 31, Group 2024 $ 2023 $ 2022 $ Director fees including bonus (excluding Chairman’s bonus) 1,100,192 910,403 707,385 Chairman’s bonus 934,007 300,000 - Auditor’s Remuneration (refer to Note 20) * 158,195 454,692 349,665 Legal and Professional fees 1,377,774 1,432,926 1,143,300 (Gain)/Loss on disposal of leases - - (179 ) FX Gains and losses 55,183 99,930 (13,577 ) Depreciation 3,866 3,797 2,423 * This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

EMPLOYEES INCLUDING OFFICERS,_2

EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS (Tables)	12 Months Ended
	Mar. 31, 2024
Employees Including Officers Executive And Non-executive Directors
DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY	DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY 2024 $ 2023 $ 2022 $ Year ended March 31, 2024 $ 2023 $ 2022 $ Group Staff costs comprised: Directors’ salaries 2,039,447 1,204,285 707,385 Wages and salaries 612,076 548,328 323,186 Social security costs 11,386 151,967 84,449 Recruitment costs - 13,750 14,259 Total employee benefits expense 2,662,909 1,918,330 1,129,279 The average monthly number of employees, including directors, employed by the group during the years ending March 31, 2024, March 31, 2023, and March 31, 2022 were: Research and Development 2 2 2 Corporate and administration 5 6 5 7 8 7

REMUNERATION OF KEY MANAGEMEN_2

REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)	12 Months Ended
	Mar. 31, 2024
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
SCHEDULE OF REMUNERATION OF DIRECTORS	Directors of the Group and Company received the following remuneration during the years ended March 31, 2024 and 2023: SCHEDULE OF REMUNERATION OF DIRECTORS Year ended March 31, 2024 2023 $’000 Directors’ Bonus Salary Share based payment expenses Directors’ Bonus Salary Share based payment expenses G. Cerrone (1) 376 934 - - 145 300 - - G Jacob - 196 392 526 - 217 433 834 W Simon 40 - - 10 39 - - - J Brancaccio 56 - - 30 39 - - 24 B Denoyer (3) 40 - - 11 39 - - 18 512 1,130 392 577 262 517 433 876 Year ended March 31, $’000 2022 Directors Bonus Salary Share based G. Cerrone (1) 164 - - - G Jacob - 75 350 1,579 W Simon 44 - - 1 K. Shailubhai (2) 18 - - (15 ) J Brancaccio 42 - - 20 B Denoyer (3) 15 - - 4 283 75 350 1,589 (1) Gabriele Cerrone’s bonus awarded for $ 939 614 320 Gabriele Cerrone’s bonus awarded for $ 300 150 150 (2) K Shailubhai resigned as Director on 17 June 2021 (3) Bernard Denoyer was appointed as Director on 24 November 2021
SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS	The following share options were granted to Directors in the year: SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS 2024 2023 2022 Number of Number of Number of J Brancaccio 60,000 15,385 15,385 G Jacob 50,000 84,615 200,000 W Simon 60,000 6,154 - B Denoyer 10,000 3,077 15,384 180,000 109,231 230,769
SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION	SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION 2024 2023 2022 $’000 $’000 $’000 Short-term employee benefits 2,559 1,500 1,026 Share based payments 1,005 1,273 1,815 Total 3,564 2,773 2,841

TAXATION (Tables)

TAXATION (Tables)	12 Months Ended
	Mar. 31, 2024
Deferred tax expense (income) [abstract]
SCHEDULE OF TAX CREDIT PERIOD	SCHEDULE OF TAX CREDIT PERIOD Year ended March 31, 2024 $ 2023 $ 2022 $ Group Current year tax charge/(credit) 55,280 - (509,282 ) Adjustments in respect of prior periods (32,864 ) (12,202 ) (277,239 ) Deferred tax Origination and reversal of timing differences - - - Total tax charge/(credit) for the period 22,416 (12,202 ) (786,521 ) The tax charge/(credit) for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows: Loss before taxation (16,803,045 ) (13,283,888 ) (6,217,566 ) Loss charged at standard rate of corporation tax 19 (3,192,578 ) (2,523,939 ) (1,181,337 ) Tax losses arising in the year not recognized 3,032,344 2,279,050 524,870 Tax losses surrendered for Research and Development - - 667,335 Expenses not deductible for taxation 220,187 241,985 370,306 Tax increase from effect of capital allowances and depreciation 748 124 (3 ) Research and Development tax claim - - (509,282 ) Research and Development enhanced expenditure - - (377,187 ) Research and Development tax credits claimed in respect of previous periods (32,864 ) (12,202 ) (277,240 ) Consolidation adjustment in relation to foreign exchange movements (5,421 ) 2,780 (3,983 ) Total tax charge/(credit) for the period 22,416 (12,202 ) (786,521 )

FINANCE INCOME AND COSTS (Table

FINANCE INCOME AND COSTS (Tables)	12 Months Ended
	Mar. 31, 2024
SCHEDULE OF FINANCE COST	SCHEDULE OF FINANCE COST 2024 $ 2023 $ 2022 $ Year ended March 31, 2024 $ 2023 $ 2022 $ Finance Income Interest income - - - Total finance income - - - Finance Expenses Interest expense on lease liabilities - - - Interest expense on related party loan (1,053,313 ) (96,687 ) - Total finance expenses (1,053,313 ) (96,687 ) -

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Mar. 31, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Details of the Group’s property, plant and equipment are as follows: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT $ IT equipment Total Cost At 1 April 2023 15,315 15,315 Additions - - Disposals (5,037 ) (5,037 ) Foreign exchange 189 189 At March 31, 2024 10,467 10,467 Depreciation At 1 April 2023 8,099 8,099 Charge in year 3,866 3,866 Write Off Disposals (5,037 ) (5,037 ) Foreign exchange 189 189 At March 31, 2024 7,117 7,117 Net Book Value as at March 31, 2024 3,350 3,350 $ IT equipment Total Cost At April 1, 2022 9,779 9,779 Additions 5,916 5,916 Disposals - - Foreign exchange (380 ) (380 ) At March 31, 2023 15,315 15,315 Depreciation At April 1, 2022 4,554 4,554 Charge in year 3,797 3,797 Foreign exchange (252 ) (252 ) At March 31, 2023 8,099 8,099 Net Book Value as at March 31, 2023 7,216 7,216
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT	The Group’s property, plant and equipment is located in the following operating segments: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT Group Net Book Value $ UK 1,859 US 1,491 Total 3,350 Property, plant and equipment 3,350 Group Net Book Value $ UK 3,433 US 3,783 Total 7,216 Property, plant and equipment 7,216

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Receivables
SUMMARY OF PREPAID EXPENSES AND OTHER RECEIVABLES	SUMMARY OF PREPAID EXPENSES AND OTHER RECEIVABLES $ 2024 2023 Year ended March 31, $ 2024 2023 Group Other receivables 5,585 340,848 VAT receivable 16,227 80,099 Prepayments 130,126 171,248 Prepaid expenses and other receivables 151,938 592,195

TRADE AND OTHER PAYABLES (Table

TRADE AND OTHER PAYABLES (Tables)	12 Months Ended
	Mar. 31, 2024
Trade and other payables [abstract]
SCHEDULE OF TRADE AND OTHER PAYABLES	SCHEDULE OF TRADE AND OTHER PAYABLES $ 2024 2023 Year ended March 31, $ 2024 2023 Group Trade payables 6,128,132 2,314,581 Other payables 103,830 73,197 Accruals 504,657 1,545,410 Bonus accrual 325,518 329,667 Trade and other payables 7,062,137 4,262,855

CAPITAL AND RESERVES (Tables)

CAPITAL AND RESERVES (Tables)	12 Months Ended
	Mar. 31, 2024
Issued capital [abstract]
SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES	The Company is authorized to issue an unlimited number of nil par value shares of a single class. SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES Shares Share capital Issued ordinary shares of US$0.00 each Number $ At March 31, 2022 per 20-F Annual Report 1,374,415,468 123,976,510 Group Reorganization : Share Consolidation 65 to 1 Restated at 31 March 2022 21,144,745 123,976,510 Issue of share (IPO) – May 2022 625,000 2,500,000 Issue of share (IPO) – Cost of fundraising – May 2022 - (742,979 ) Expenses settled in shares 33,500 86,028 Issue of share (IPO) – March 2023 3,716,529 5,741,335 Issue of share (IPO) – Cost of fundraising – March 2023 - (175,000 ) At March 31, 2023 25,519,774 131,385,892 Issue of share for fundraising, net Sept-Dec 2023 4,159,270 6,208,508 Expenses settled in shares 1,557,272 2,368,287 Issuance of Shares to related party – Loan Conversion 2,100,000 3,150,000 At March 31, 2024 33,336,316 143,112,687

SHARE OPTIONS AND WARRANTS (Tab

SHARE OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2024
Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]
SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE	SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE 2024 2023 Options Weighted Options Weighted Outstanding at April 1 1,696,451 3.85 1,113,841 4.86 Granted 727,500 1.53 612,610 1.04 Forfeited (2,301 ) 2.13 (30,000 ) - Exercised - - - - Outstanding at March 31 2,421,650 3.34 1,696,451 3.85 Exercisable at March 31 894,956 4.34 560,082 4.41 2022 Options Weighted Outstanding at April 1 934,615 4.48 Granted 433,072 5.46 Forfeited (253,846 ) 3.84 Exercised - - Outstanding at March 31 1,113,841 4.86 Exercisable at March 31 222,115 4.78
SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES	Share options outstanding at the end of the year have the following expiry dates and exercise prices: SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES Grant Date Expiry Date Exercise Price $ Share Options as at March 31, 2024 July 6, 2018 July 6, 2025 3.69 30,769 August 20, 2020 August 19, 2028 12.72 11,538 January 6, 2021 January 5, 2031 4.10 615,384 January 21, 2021 January 11, 2031 6.48 23,076 April 15, 2021 April 15, 2031 6.47 76,923 August 31, 2021 August 31, 2031 4.02 221,538 January 31,2022 January 30, 2032 6.57 134,613 August 1, 2022 July 31,2027 4.10 10,000 September 20, 2022 September 19, 2027 4.10 28,000 November 22,2022 November 23,2022 5.13 76,923 March 14, 2023 March 13, 2027 1.85 465,386 July 26, 2023 July 26,2033 1.53 260,000 October 20, 2023 October 20, 2033 1.57 85,000 November 20, 2023 November 20, 2033 1.71 65,000 November 24, 2023 November 24,2033 1.65 40,000 March 1, 2024 March 1,2034 1,33 20,000 March 13, 2024 March 13, 2034 1.46 257,500 Total 2,421,650
SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED	The model inputs for options granted during the year ended March 31, 2024 valued under the Black Scholes Valuation model are: SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED Grant Date March 1, 2024 March 13, 2024 Grant date share price $ 1.33 $ 1.46 Exercise share price $ 1.33 $ 1.46 Vesting periods 50% over two years 33.3% over three years Risk free rate 4.18 % 4.19 % Expected volatility 91.0 % 91.0 % Option life 4 4 Grant Date July 26, October 20, November 20, November 24, Grant date share price $ 1.53 $ 1.57 $ 1.71 $ 1.65 Exercise share price $ 1.53 $ 1.57 $ 1.71 $ 1.65 Vesting periods 25% over four years 33.3% over three years 25% over four years 25% over four years Risk free rate 3.91 % 4.31 % 3.70 % 3.91 % Expected volatility 68.8 % 72.0 % 72.0 % 72.0 % Option life 4 4 4 4 The model inputs for options granted during the year ended March 31, 2023 valued under the Black Scholes Valuation model are: Grant Date August 1, September 20, November 22, March 14, Grant date share price 5 p 5 p 6.3 p 2.5 p Exercise share price 5 p 5 p 6.3 p 2.5 p Vesting periods 25% each quarter 100% in one year Fully vested 25% over four years Risk free rate 1.47 % 3.26 % 3.16 % 3.2 % Expected volatility 81.2 % 81.8 % 68.3 % 125 % Option life 2 2 2 4
SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE	SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE March 31, 2024 March 31, 2023 Warrants Weighted Average exercise price (cents) Warrants Weighted Average exercise price (cents) Outstanding at April 1 563,986 397 563,986 397 Granted - - - - Exercised - - - - Outstanding at March 31 563,986 397 563,986 397 Exercisable at March 31 307,692 221 13,986 221

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Mar. 31, 2024
Disclosure of detailed information about financial instruments [abstract]
SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS	The table below summarizes the maturity profile of the Group’s financial liabilities based on contractual undiscounted payments: SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS $ Less than 3 3 to 12 months Total Group 2024 $ Less than 3 3 to 12 months Total Trade and other payables 1,028,764 6,033,373 7,062,137 Related party payables 25,019 333,690 358,709 Total 1,053,783 6,367,063 7,420,846 $ Less than 3 3 to 12 months Total Group 2023 $ Less than 3 3 to 12 months Total Trade and other payables 2,800,918 1,461,937 4,262,855 Related party payables - 2,994,302 2,994,302 Total 2,800,918 4,456,239 7,257,157

BASIC AND DILUTED LOSS PER SH_2

BASIC AND DILUTED LOSS PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2024
Earnings per share [abstract]
SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS	SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS Year ended 2024 2023 (Loss) attributable to equity holders of the company ($) (16,825,461 ) (13,271,685 ) Weighted average number of ordinary shares in issue (adjusted) 29,343,727 22,257,058 Basic and dilutive loss per share (dollars per share) (0.57 ) (0.61 ) Year ended 2022 (Loss) attributable to equity holders of the company ($) (5,431,045 ) Weighted average number of ordinary shares in issue (adjusted) 15,064,813 Basic and dilutive loss per share (dollars per share) (0.36 )

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Mar. 31, 2024
Presentation of leases for lessee [abstract]
SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES	At March 31, 2024 and March 31, 2023, the company had annual commitments under non-cancellable operating leases: SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES Operating leases which expire: March 31, 2024 March 31, 2023 $ $ Within one year 6,660 6,000

AUDITOR_S RENUMERATION (Tables)

AUDITOR’S RENUMERATION (Tables)	12 Months Ended
	Mar. 31, 2024
Notes and other explanatory information [abstract]
SCHEDULE OF COMPANY AUDITORS FEES	During the period, the group obtained the following services from the company’s auditors PKF, our independent registered public accounting firm and Mazars, our previous independent registered public accounting firm.: SCHEDULE OF COMPANY AUDITORS FEES Mazars LLP March 31, 2024 March 3,1 2023 March 31, 2022 $ $ $ Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements - 106,927 200,773 Fees payable to the company’s auditors for other services: Audit-related assurance services 7,354 227,208 148,892 Total auditor’s remuneration 7,354 334,135 349,665 PKF Littlejohn LLP March 31, 2024 March 31, 2023 March 31, 2022 $ $ $ Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements 125,701 120,557 - Fees payable to the company’s auditors for other services: Audit-related assurance services 25,140 - - Total auditor’s remuneration 150,841 120,557 -

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Mar. 31, 2024
Cash and cash equivalents [abstract]
SCHEDULE OF CASH AND CASH EQUIVALENT	Cash and cash equivalents consist of the following: SCHEDULE OF CASH AND CASH EQUIVALENT March 31, 2024 March 31, 2023 $ $ Cash at bank and in hand: GBP 275,342 471,974 EURO 898 - USD 550,608 3,573,407 826,848 4,045,381

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2024
SCHEDULE OF MILESTONES PAYMENT	SCHEDULE OF MILESTONES PAYMENT (a) First Patient Enrolled in a Phase I Human Clinical trial $ 300,000 (b) First Patient Enrolled in a Phase II Human Clinical trial $ 600,000 (c) First Patient Enrolled in a Phase III Human Clinical trial $ 1,500,000

DISCLOSURE OF ESTIMATED USEFUL

DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)	12 Months Ended
	Mar. 31, 2024
Computer equipment [member]
IFRSStatementLineItems [Line Items]
Estimated useful lives	3 years

SCHEDULE OF RECLASSIFICATION OF

SCHEDULE OF RECLASSIFICATION OF CONSOLIDATED STATEMENT OF OPERATIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
IFRSStatementLineItems [Line Items]
Research and development	$ (8,243,571)	$ (6,337,698)	$ (1,609,558)	[1]
Operating expenses	(7,506,161)	(6,849,502)	(4,608,008)	[1]
Total operating expenses	(15,749,732)	(13,187,200)	(6,217,566)	[1]
Comprehensive loss	$ (16,684,366)	$ (13,712,700)	(6,268,197)	[1]
Previously Reported [Member]
IFRSStatementLineItems [Line Items]
Research and development			(1,301,178)
Operating expenses			(4,916,388)
Total operating expenses			(6,217,566)
Comprehensive loss			(6,268,197)
Adjustment [Member]
IFRSStatementLineItems [Line Items]
Research and development			(308,380)
Operating expenses			308,380
Total operating expenses
Comprehensive loss
[1]Refer to Note 2A and 18A

ACCOUNTING POLICIES (Details Na

ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	5 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022		Sep. 30, 2024	Jul. 26, 2024	Mar. 31, 2021	Dec. 31, 2018
IFRSStatementLineItems [Line Items]
Accumulated deficit	$ 125,697,719		$ 142,523,180	$ 125,697,719						$ 109,000,000
Net loss			16,825,461	13,271,685	$ 5,431,045	[1]
Net cash used in operating activities			9,490,537	7,695,242	5,468,065
Cash	4,045,381		$ 826,848	$ 4,045,381	$ 2,700,724				$ 6,889,329
Initial public offering	2,500,000
Private placement	$ 11,400,000
Non-adjusting event [member]
IFRSStatementLineItems [Line Items]
Cash							$ 400,000	$ 300,000
Rate of cash burn/spend		$ 2,600,000
[1]Refer to Note 2A and 18A

SCHEDULE OF OPERATING EXPENSES

SCHEDULE OF OPERATING EXPENSES (Details) - USD ($)		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Expenses by nature [abstract]
Director fees including bonus (excluding Chairman’s bonus)		$ 1,100,192	$ 910,403	$ 707,385
Chairman’s bonus		934,007	300,000
Auditor’s Remuneration (refer to Note 20)	[1]	158,195	454,692	349,665
Legal and Professional fees		1,377,774	1,432,926	1,143,300
(Gain)/Loss on disposal of leases				(179)
FX Gains and losses		55,183	99,930	(13,577)
Depreciation		$ 3,866	$ 3,797	$ 2,423
[1]This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

DISCLOSURE OF EMPLOYEES COST AN

DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)	12 Months Ended
	Mar. 31, 2024 USD ($) Integer	Mar. 31, 2023 USD ($) Integer	Mar. 31, 2022 USD ($) Integer
IFRSStatementLineItems [Line Items]
Directors’ salaries	$ 2,039,447	$ 1,204,285	$ 707,385
Wages and salaries	612,076	548,328	323,186
Social security costs	11,386	151,967	84,449
Recruitment costs		13,750	14,259
Total employee benefits expense	$ 2,662,909	$ 1,918,330	$ 1,129,279
Total number of employees | Integer	7	8	7
Research and development [member]
IFRSStatementLineItems [Line Items]
Total number of employees | Integer	2	2	2
Corporate and administration [member]
IFRSStatementLineItems [Line Items]
Total number of employees | Integer	5	6	5

EMPLOYEES INCLUDING OFFICERS,_3

EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Employees Including Officers Executive And Non-executive Directors
Pension contribution	$ 5,598	$ 6,510	$ 2,622

SCHEDULE OF REMUNERATION OF DIR

SCHEDULE OF REMUNERATION OF DIRECTORS (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Disclosure of transactions between related parties [line items]
Directors' fees		$ 512	$ 262	$ 283
Bonus		1,130	517	75
Salary		392	433	350
Share based payment expenses		577	876	1,589
G. Cerrone [member]
Disclosure of transactions between related parties [line items]
Directors' fees	[1]	376	145	164
Bonus	[1]	934	300
Salary	[1]
Share based payment expenses	[1]
G Jacob [member]
Disclosure of transactions between related parties [line items]
Directors' fees
Bonus		196	217	75
Salary		392	433	350
Share based payment expenses		526	834	1,579
W Simon [member]
Disclosure of transactions between related parties [line items]
Directors' fees		40	39	44
Bonus
Salary
Share based payment expenses		10		1
J Brancaccio [member]
Disclosure of transactions between related parties [line items]
Directors' fees		56	39	42
Bonus
Salary
Share based payment expenses		30	24	20
B Denoyer [member]
Disclosure of transactions between related parties [line items]
Directors' fees	[2]	40	39	15
Bonus	[2]
Salary	[2]
Share based payment expenses	[2]	$ 11	$ 18	4
K. Shailubhai [member]
Disclosure of transactions between related parties [line items]
Directors' fees	[3]			18
Bonus	[3]
Salary	[3]
Share based payment expenses	[3]			$ (15)
[1]Gabriele Cerrone’s bonus awarded for $ 939 614 320

SCHEDULE OF REMUNERATION OF D_2

SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2022	Mar. 31, 2024	Mar. 31, 2023
Disclosure of transactions between related parties [line items]
Bonus awarded			$ 150
G. Cerrone [member]
Disclosure of transactions between related parties [line items]
Bonus awarded	$ 150	$ 939	$ 300
Office of Research Administration [Member]
Disclosure of transactions between related parties [line items]
Bonus awarded		614
Global Private Placing [Member]
Disclosure of transactions between related parties [line items]
Bonus awarded		$ 320

SCHEDULE OF SHARE OPTIONS GRANT

SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details) - shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	727,500	612,610	433,072
Directors [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	180,000	109,231	230,769
Directors [member] | J Brancaccio [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	60,000	15,385	15,385
Directors [member] | G Jacob [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	50,000	84,615	200,000
Directors [member] | W Simon [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	60,000	6,154
Directors [member] | B Denoyer [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options	10,000	3,077	15,384

SCHEDULE OF KEY MANAGEMENT PERS

SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details) - Key management personnel of entity or parent [member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
IFRSStatementLineItems [Line Items]
Short-term employee benefits	$ 2,559	$ 1,500	$ 1,026
Share based payments	1,005	1,273	1,815
Total	$ 3,564	$ 2,773	$ 2,841

SCHEDULE OF TAX CREDIT PERIOD (

SCHEDULE OF TAX CREDIT PERIOD (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Deferred tax expense (income) [abstract]
Current year tax charge/(credit)	$ 55,280		$ (509,282)
Adjustments in respect of prior periods	(32,864)	(12,202)	(277,239)
Origination and reversal of timing differences
Total tax charge/(credit) for the period	22,416	(12,202)	(786,521)
Loss before taxation	(16,803,045)	(13,283,888)	(6,217,566)
Loss charged at standard rate of corporation tax 19%	(3,192,578)	(2,523,939)	(1,181,337)
Tax losses arising in the year not recognized	3,032,344	2,279,050	524,870
Tax losses surrendered for Research and Development			667,335
Expenses not deductible for taxation	220,187	241,985	370,306
Tax increase from effect of capital allowances and depreciation	748	124	(3)
Research and Development tax claim			(509,282)
Research and Development enhanced expenditure			(377,187)
Research and Development tax credits claimed in respect of previous periods	(32,864)	(12,202)	(277,240)
Consolidation adjustment in relation to foreign exchange movements	$ (5,421)	$ 2,780	$ (3,983)

SCHEDULE OF TAX CREDIT PERIOD_2

SCHEDULE OF TAX CREDIT PERIOD (Details) (Paranthetical)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Deferred tax expense (income) [abstract]
Corporation tax rate	19%	19%	19%

TAXATION (Details Narrative)

TAXATION (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Deferred tax expense (income) [abstract]
Tax effect of tax losses	$ 38,992,275	$ 23,903,092	$ 15,870,525

SCHEDULE OF FINANCE COST (Detai

SCHEDULE OF FINANCE COST (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Interest income
Total finance income
Interest expense on lease liabilities
Interest expense on related party loan	(1,053,313)	(96,687)
Total finance expenses	$ (1,053,313)	$ (96,687)		[1]
[1]Refer to Note 2A and 18A

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
IFRSStatementLineItems [Line Items]
Property and equipment, cost, beginning balance	$ 15,315	$ 9,779
Additions		5,916
Disposals	(5,037)
Foreign exchange	189	(380)
Property and equipment, cost, ending balance	10,467	15,315
Depreciation, beginning balance	8,099	4,554
Charge in year	3,866	3,797
Write Off Disposals	(5,037)
Foreign exchange	189	(252)
Depreciation, ending balance	7,117	8,099
Depreciation, net book value	3,350	7,216
IT equipment [member]
IFRSStatementLineItems [Line Items]
Property and equipment, cost, beginning balance	15,315	9,779
Additions		5,916
Disposals	(5,037)
Foreign exchange	189	(380)
Property and equipment, cost, ending balance	10,467	15,315
Depreciation, beginning balance	8,099	4,554
Charge in year	3,866	3,797
Write Off Disposals	(5,037)
Foreign exchange	189	(252)
Depreciation, ending balance	7,117	8,099
Depreciation, net book value	$ 3,350	$ 7,216

SCHEDULE OF PROPERTY PLANT AN_2

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ 3,350	$ 7,216
UK [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	1,859	3,433
United State [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ 1,491	$ 3,783

SUMMARY OF PREPAID EXPENSES AND

SUMMARY OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Prepaid Expenses And Other Receivables
Other receivables	$ 5,585	$ 340,848
VAT receivable	16,227	80,099
Prepayments	130,126	171,248
Prepaid expenses and other receivables	$ 151,938	$ 592,195

SCHEDULE OF TRADE AND OTHER PAY

SCHEDULE OF TRADE AND OTHER PAYABLES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Trade and other payables [abstract]
Trade payables	$ 6,128,132	$ 2,314,581
Other payables	103,830	73,197
Accruals	504,657	1,545,410
Bonus accrual	325,518	329,667
Trade and other payables	$ 7,062,137	$ 4,262,855

SCHEDULE OF AUTHORIZED ISSUE UN

SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
IFRSStatementLineItems [Line Items]
Balance	$ (2,053,237)	$ 2,947,402	$ 5,319,408
Expenses settled in shares	3,452,769	86,028
Balance	$ (5,879,582)	$ (2,053,237)	$ 2,947,402
Issued Capital [member]
IFRSStatementLineItems [Line Items]
Balance, shares	25,519,774	1,374,415,468
Balance	$ 131,385,892	$ 123,976,510
Issue of share (IPO) - May 2022, shares		625,000
Issue of share (IPO) - May 2022		$ 2,500,000
Issue of share (IPO) - Cost of fundraising - May 2022, shares
Issue of share (IPO) - Cost of fundraising - May 2022		$ (742,979)
Expenses settled in shares	1,557,272	33,500
Expenses settled in shares, value	$ 2,368,287	$ 86,028
Issue of share (IPO) - March 2023, shares		3,716,529
Issue of share (IPO) - March 2023		$ 5,741,335
Issue of share (IPO) - Cost of fundraising - March 2023, shares
Issue of share (IPO) - Cost of fundraising - March 2023		$ (175,000)
Issue of share for fundraising, net Sept-Dec 2023, Shares	4,159,270
Issue of share for fundraising, net Sept-Dec 2023	$ 6,208,508
Issuance of Shares to related party - Loan Conversion, Shares	2,100,000
Issuance of Shares to related party - Loan Conversion	$ 3,150,000
Balance, shares	33,336,316	25,519,774	1,374,415,468
Balance	$ 143,112,687	$ 131,385,892	$ 123,976,510
Issued Capital [member] | Increase (decrease) due to corrections of prior period errors [member]
IFRSStatementLineItems [Line Items]
Balance, shares		21,144,745
Balance		$ 123,976,510
Balance, shares			21,144,745
Balance			$ 123,976,510

CAPITAL AND RESERVES (Details N

CAPITAL AND RESERVES (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Issued capital [abstract]
Payment of dividend	$ 0	$ 0

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)	12 Months Ended
	Mar. 31, 2024 shares $ / shares	Mar. 31, 2023 shares $ / shares	Mar. 31, 2022 shares $ / shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]
Beginning balance, Options outstanding | shares	1,696,451	1,113,841	934,615
Beginning balance, weighted average exercise price | $ / shares	$ 3.85	$ 4.86	$ 4.48
Options, Granted | shares	727,500	612,610	433,072
Weighted average exercise price granted | $ / shares	$ 1.53	$ 1.04	$ 5.46
Options, Forfeited | shares	(2,301)	(30,000)	(253,846)
Weighted average exercise price forfeited | $ / shares	$ 2.13		$ 3.84
Options, Exercised | shares
Weighted average exercise price exercised | $ / shares
Ending balance, Options outstanding | shares	2,421,650	1,696,451	1,113,841
Ending balance, weighted average exercise price | $ / shares	$ 3.34	$ 3.85	$ 4.86
Options, Exercisable | shares	894,956	560,082	222,115
Weighted average exercise price exercisable | $ / shares	$ 4.34	$ 4.41	$ 4.78

SCHEDULE OF SHARE OPTIONS OUTST

SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)

12 Months Ended

Mar. 14, 2024 $ / shares

Mar. 13, 2024 $ / shares

Mar. 01, 2024 $ / shares

Nov. 24, 2023 $ / shares

Nov. 22, 2023 $ / shares

Nov. 20, 2023 $ / shares

Oct. 20, 2023 $ / shares

Sep. 20, 2023 $ / shares

Aug. 01, 2023 $ / shares

Jul. 26, 2023 $ / shares

Mar. 31, 2024 shares $ / shares

Mar. 31, 2023 shares

Mar. 31, 2022 shares

Mar. 31, 2021 shares

IFRSStatementLineItems [Line Items]

Exercise Price | $ / shares

$ 2.5

$ 1.46

$ 1.33

$ 1.65

$ 6.3

$ 1.71

$ 1.57

$ 5

$ 5

$ 1.53

Share Options, Outstanding | shares

2,421,650

1,696,451

1,113,841

934,615

July 6, 2018 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jul. 06, 2025

Exercise Price | $ / shares

$ 3.69

Share Options, Outstanding | shares

30,769

August 20, 2020 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Aug. 19, 2028

Exercise Price | $ / shares

$ 12.72

Share Options, Outstanding | shares

11,538

January 6, 2021 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jan. 05, 2031

Exercise Price | $ / shares

$ 4.10

Share Options, Outstanding | shares

615,384

January 21, 2021 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jan. 11, 2031

Exercise Price | $ / shares

$ 6.48

Share Options, Outstanding | shares

23,076

April 15, 2021 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Apr. 15, 2031

Exercise Price | $ / shares

$ 6.47

Share Options, Outstanding | shares

76,923

August 31, 2021 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Aug. 31, 2031

Exercise Price | $ / shares

$ 4.02

Share Options, Outstanding | shares

221,538

January 31, 2022 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jan. 30, 2032

Exercise Price | $ / shares

$ 6.57

Share Options, Outstanding | shares

134,613

August 1, 2022 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jul. 31, 2027

Exercise Price | $ / shares

$ 4.10

Share Options, Outstanding | shares

10,000

September 20, 2022 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Sep. 19, 2027

Exercise Price | $ / shares

$ 4.10

Share Options, Outstanding | shares

28,000

November 22, 2022 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Nov. 23, 2022

Exercise Price | $ / shares

$ 5.13

Share Options, Outstanding | shares

76,923

March 14, 2023 [member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Mar. 13, 2027

Exercise Price | $ / shares

$ 1.85

Share Options, Outstanding | shares

465,386

July 26, 2023 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Jul. 26, 2033

Exercise Price | $ / shares

$ 1.53

Share Options, Outstanding | shares

260,000

October 20, 2023 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Oct. 20, 2033

Exercise Price | $ / shares

$ 1.57

Share Options, Outstanding | shares

85,000

November 20, 2023 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Nov. 20, 2033

Exercise Price | $ / shares

$ 1.71

Share Options, Outstanding | shares

65,000

November 24, 2023 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Nov. 24, 2033

Exercise Price | $ / shares

$ 1.65

Share Options, Outstanding | shares

40,000

March 1, 2024 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Mar. 01, 2034

Exercise Price | $ / shares

$ 1.33

Share Options, Outstanding | shares

20,000

March 13, 2024 [Member]

IFRSStatementLineItems [Line Items]

Expiration date of outstanding

Mar. 13, 2034

Exercise Price | $ / shares

$ 1.46

Share Options, Outstanding | shares

257,500

SCHEDULE OF SHARE BASED PAYMENT

SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details) - $ / shares	Mar. 14, 2024	Mar. 13, 2024	Mar. 01, 2024	Nov. 24, 2023	Nov. 22, 2023	Nov. 20, 2023	Oct. 20, 2023	Sep. 20, 2023	Aug. 01, 2023	Jul. 26, 2023
Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]
Grant date share price	$ 2.5	$ 1.46	$ 1.33	$ 1.65	$ 6.3	$ 1.71	$ 1.57	$ 5	$ 5	$ 1.53
Exercise share price	$ 2.5	$ 1.46	$ 1.33	$ 1.65	$ 6.3	$ 1.71	$ 1.57	$ 5	$ 5	$ 1.53
Vesting periods	25% over four years	33.3% over three years	50% over two years	25% over four years	Fully vested	25% over four years	33.3% over three years	100% in one year	25% each quarter	25% over four years
Risk free rate	3.20%	4.19%	4.18%	3.91%	3.16%	3.70%	4.31%	3.26%	1.47%	3.91%
Expected volatility	125%	91%	91%	72%	68.30%	72%	72%	81.80%	81.20%	68.80%
Option life	4 years	4 years	4 years	4 years	2 years	4 years	4 years	2 years	2 years	4 years

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details) - Warrant reserve [member]	12 Months Ended
	Mar. 31, 2024 shares $ / shares	Mar. 31, 2023 shares $ / shares
IFRSStatementLineItems [Line Items]
Warrants outstanding, beginning balance | shares	563,986	563,986
Weighted average exercise price, outstanding beginning balance | $ / shares	$ 397	$ 397
Warrants granted | shares
Weighted average exercise price, granted | $ / shares
Warrants exercised | shares
Weighted average exercise price, exercised | $ / shares
Warrants outstanding, ending balance | shares	563,986	563,986
Weighted average exercise price, outstanding ending balance | $ / shares	$ 397	$ 397
Warrants exercisable | shares	307,692	13,986
Weighted average exercise price, exercisable | $ / shares	$ 221	$ 221

SHARE OPTIONS AND WARRANTS (Det

SHARE OPTIONS AND WARRANTS (Details Narrative)	1 Months Ended	12 Months Ended
	May 31, 2020 shares $ / shares	Mar. 31, 2024 USD ($) shares $ / shares	Mar. 31, 2023 USD ($) shares $ / shares	Mar. 31, 2022 shares
IFRSStatementLineItems [Line Items]
Number of option were exercised | shares
Fair value charge of share option instruments deemed		$ 1,146,835	$ 1,649,386
Share based payment charge		1,119,854	1,273,716
Share based payment charge forfeiture		$ 1,419	$ 12,412
Weighted average contractual life of options outstanding		7 years 7 months 6 days	5 years 8 months 23 days
Number of warrants granted or exercised | shares		0
Lieu of professional fees [member]
IFRSStatementLineItems [Line Items]
Warrants granted | shares	13,986
Weighted average exercise price, granted | $ / shares	$ 178.75
Warrant reserve [member]
IFRSStatementLineItems [Line Items]
Share based payment charge		$ 28,963	$ 61,721
Consideration paid (received)		$ 563,986
Warrants exercisable price | $ / shares		$ 292.5
Warrants granted | shares
Weighted average exercise price, granted | $ / shares
Fair value of warrants			$ 11,194

SUMMARY OF FINANCIAL LIABILITIE

SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
IFRSStatementLineItems [Line Items]
Trade and other payables	$ 7,062,137	$ 4,262,855
Related party payables	358,709	2,994,302
Total	7,420,846	7,257,157
Less than 3 months [member]
IFRSStatementLineItems [Line Items]
Trade and other payables	1,028,764	2,800,918
Related party payables	25,019
Total	1,053,783	2,800,918
3 to 12 Months [member]
IFRSStatementLineItems [Line Items]
Trade and other payables	6,033,373	1,461,937
Related party payables	333,690	2,994,302
Total	$ 6,367,063	$ 4,456,239

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
	Oct. 25, 2023	Apr. 30, 2024	Feb. 28, 2023	Aug. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Disclosure of transactions between related parties [line items]
Settlement of liabilities on behalf of entity by related party, related party transactions					$ 35,347	$ 433,140
Issued capital [member]
Disclosure of transactions between related parties [line items]
Convertible loan note conversion	2,100,000						4,847,483
Non-adjusting event [member]
Disclosure of transactions between related parties [line items]
Settlement of liabilities by entity on behalf of related party, related party transactions		$ 230,000
Tiziana Life Sciences Ltd. [member]
Disclosure of transactions between related parties [line items]
Amounts payable related party transaction					75,267
Tiziana Life Sciences Ltd. [member] | Shortterm Credit Facility [Member]
Disclosure of transactions between related parties [line items]
Maximum borrowing capacity amount				$ 2,000,000
Description of borrowing interest rates				The loan was available for a period of 6 months upon first draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the 6-month period.
Interest rate				16%
Tiziana Life Sciences Ltd. [member] | Additional Shortterm Credit Facility [Member]
Disclosure of transactions between related parties [line items]
Maximum borrowing capacity amount			$ 500,000
Additional interest rate				4%
Borrowings	$ 2,000,000					488,009
Accrued interest	$ 1,150,000					7,902
Repayment of principal of borrowings						7,902
Tiziana Life Sciences Ltd. [member] | Service Agreement [member]
Disclosure of transactions between related parties [line items]
Service received related party transaction					139,963	159,501
Amounts payable related party transaction					297,870	$ 184,150
John Brancaccio [Member]
Disclosure of transactions between related parties [line items]
Directors fees					13,408
Bernard Denoyer [Member]
Disclosure of transactions between related parties [line items]
Directors fees					13,408
Gary Jacobs [Member]
Disclosure of transactions between related parties [line items]
Directors fees					29,167
Willy Simon [Member]
Disclosure of transactions between related parties [line items]
Directors fees					13,408
Gabriele Cerrone [Member]
Disclosure of transactions between related parties [line items]
Directors fees					$ 62,850

SUMMARY OF INCOME AND SHARE DAT

SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Earnings per share [abstract]
(Loss) attributable to equity holders of the company	$ (16,825,461)	$ (13,271,685)	$ (5,431,045)
Weighted average number of ordinary shares in issue	29,343,727	22,257,058	15,064,813
Basic loss per share	$ (0.57)	$ (0.61)	$ (0.36)	[1]
Dilutive loss per share	$ (0.57)	$ (0.61)	$ (0.36)	[1]
[1]Refer to Note 2A and 18A

SCHEDULE OF CONTRACTUAL MATURIT

SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Not later than one year [member]
IFRSStatementLineItems [Line Items]
Within one year	$ 6,660	$ 6,000

SCHEDULE OF COMPANY AUDITORS FE

SCHEDULE OF COMPANY AUDITORS FEES (Details) - USD ($)		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Disclosure of defined benefit plans [line items]
Total auditor’s remuneration	[1]	$ 158,195	$ 454,692	$ 349,665
Mazars LLP [member]
Disclosure of defined benefit plans [line items]
Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements			106,927	200,773
Audit-related assurance services		7,354	227,208	148,892
Total auditor’s remuneration		7,354	334,135	349,665
PKF Littlejohn LLP [member]
Disclosure of defined benefit plans [line items]
Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements		125,701	120,557
Audit-related assurance services		25,140
Total auditor’s remuneration		$ 150,841	$ 120,557
[1]This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

SCHEDULE OF CASH AND CASH EQUIV

SCHEDULE OF CASH AND CASH EQUIVALENT (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Disclosure of fair value measurement of assets [line items]
Cash at bank and in hand	$ 826,848	$ 4,045,381
GBP [Member]
Disclosure of fair value measurement of assets [line items]
Cash at bank and in hand	275,342	471,974
Euro Member Countries, Euro
Disclosure of fair value measurement of assets [line items]
Cash at bank and in hand	898
USD [member]
Disclosure of fair value measurement of assets [line items]
Cash at bank and in hand	$ 550,608	$ 3,573,407

SCHEDULE OF MILESTONES PAYMENT

SCHEDULE OF MILESTONES PAYMENT (Details)	12 Months Ended
	Mar. 31, 2024 USD ($)
Phase I Human Clinical Trial [member]
IFRSStatementLineItems [Line Items]
Amount of licensed product or service	$ 300,000
Phase II Human Clinical Trial [member]
IFRSStatementLineItems [Line Items]
Amount of licensed product or service	600,000
Phase III Human Clinical Trial [member]
IFRSStatementLineItems [Line Items]
Amount of licensed product or service	$ 1,500,000

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	12 Months Ended
	Mar. 31, 2024 USD ($)
Annual license maintenance fee	$ 15,000
Annual license maintenance fee, therafter	$ 10,000